PriceTargets.com logo

BioNexus Gene Lab - BGLC Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.33 As of 12/4/2025 05:00 PM ET
▼ -0.07 (-1.59%)

This chart shows the closing price for BGLC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioNexus Gene Lab Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BGLC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BGLC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for BioNexus Gene Lab in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.33.

This chart shows the closing price for BGLC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 investment analysts is to sell stock in BioNexus Gene Lab.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/2/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/30/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

BioNexus Gene Lab logo
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Read More

Today's Range

Now: $4.33
Low: $4.05
High: $4.37

50 Day Range

MA: $5.02
Low: $4.32
High: $5.65

52 Week Range

Now: $4.33
Low: $2.01
High: $15.60

Volume

89,737 shs

Average Volume

305,655 shs

Market Capitalization

$7.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

5.24

Frequently Asked Questions

What sell-side analysts currently cover shares of BioNexus Gene Lab?

The following Wall Street analysts have issued reports on BioNexus Gene Lab in the last twelve months: Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for BGLC.

What is the current price target for BioNexus Gene Lab?

0 Wall Street analysts have set twelve-month price targets for BioNexus Gene Lab in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for BioNexus Gene Lab in the next year.
View the latest price targets for BGLC.

What is the current consensus analyst rating for BioNexus Gene Lab?

BioNexus Gene Lab currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe BGLC will underperform the market and that investors should sell shares of BioNexus Gene Lab.
View the latest ratings for BGLC.

What other companies compete with BioNexus Gene Lab?

Other companies that are similar to BioNexus Gene Lab include Basel Medical Group, Marpai, Concord Medical Services, Mangoceuticals and Biorestorative Therapies. Learn More about companies similar to BioNexus Gene Lab.

How do I contact BioNexus Gene Lab's investor relations team?

BioNexus Gene Lab's physical mailing address is Tower B, Vertical Business Suite, Unit 02, Level 10 Bangsar South 8 Jalan Kerinchi, Kuala Lumpur 59200, Malaysia. The company's listed phone number is 60-1-2212-6512 and its investor relations email address is [email protected]. The official website for BioNexus Gene Lab is www.bionexusgenelab.com. Learn More about contacing BioNexus Gene Lab investor relations.